Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ILEX Oncology, Inc. (NasdaqNM:ILXO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
4545 Horizon Hill Blvd.
San Antonio, TX 78229
Phone: (210) 949-8200
Fax: (210) 949-8415
Email: astevens@ilexonc.com
Employees (last reported count): 361
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 22%
·Over the last 6 months:
 · one insider buy; 3,000  shares
 · 5 insider sells; 48.0K shares
  (0.8% of insider shares)
·Institutional: 67% (86% of float)
(167 institutions)
·Net Inst. Buying: 1.16M shares (+6.17%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ILEX Oncology, Inc. is building an oncology-focused pharmaceutical company by assembling and developing a portfolio of novel treatments both for advanced-stage cancers and for early stage cancers and pre-malignant conditions. The Company has a portfolio of eight anticancer product candidates in clinical development and several preclinical stage product candidates. In addition to its clinical development programs, ILEX is conducting drug discovery research, translational research and preclinical studies in the fields of angiogenesis inhibition and targeted medicinal phosphonate chemistry, laying the groundwork for bringing other new proprietary product candidates into its pipeline. The Company's most advanced product candidate is Campath. On May 7, 2001, the U.S. FDA cleared Campath humanized monoclonal antibody for marketing as a treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) who have been treated with alkylating agents and have failed fludarabine therapy.
More from Market Guide: Expanded Business Description

Financial Summary
ILXO is an oncology drug development company that develops cancer treatment products by identifying, developing, manufacturing and regulating approval process of oncology drugs. For the six months ended 6/30/01, revenues decreased 6% to $13.3 million. Net loss totaled $41.7 million, up from $7.9 million. Results reflect a decrease in product development revenues. Net loss also reflects a $21.1 million in-process R and D charge related to the acquisition of Symphar S.A.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Gary Woods, 57
Chairman, Director
--  --  
Richard Love, 57
Pres, CEO, Director
$403K--  
Gregory Weaver, 45
CFO, VP
201K$132K
Ze'ev Shaked, Ph.D., 55
Exec. VP, COO
213K--  
Michael Dwyer, 55
Exec. VP, CBO
299K551K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ILXOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$11.00 
Recent Price$29.95 
52-Week High
on 2-Nov-2000
$40.188
Beta1.36 
Daily Volume (3-month avg)208.0K
Daily Volume (10-day avg)252.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-16.8%
52-Week Change
relative to S&P500
+11.6%
Share-Related Items
Market Capitalization$792.7M
Shares Outstanding26.5M
Float20.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$6.41 
Earnings (ttm)-$2.83 
Earnings (mrq)-$0.50 
Sales (ttm)$1.04 
Cash (mrq)$5.28 
Valuation Ratios
Price/Book (mrq)4.67 
Price/EarningsN/A 
Price/Sales (ttm)28.75 
Income Statements
Sales (ttm)$26.8M
EBITDA (ttm)-$77.8M
Income available to common (ttm)-$72.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-34.51%
Return on Equity (ttm)-38.24%
Financial Strength
Current Ratio (mrq)7.47 
Debt/Equity (mrq)0 
Total Cash (mrq)$139.6M
Short Interest
As of 8-Aug-2001
Shares Short891.0K
Percent of Float4.3%
Shares Short
(Prior Month)
935.0K
Short Ratio4.84 
Daily Volume184.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.